Table 1. Descriptions of patient characteristics for each cohort.
| Mayo Clinic Cohort Ref. [17] * (n = 219) | TJU Cohort Ref. [21] (n = 139) | |
|---|---|---|
| Age [Mean (SD)] | 63.28 (7.26) | 60.71 (7.24) |
| Gleason Score (%) | ||
| 6 | 7 | 16 |
| 7 | 51 | 57 |
| 8–10 | 42 | 27 |
| Pathological Features (%) | ||
| ECE | 43 | 82 |
| SVI | 37 | 38 |
| PSM | 56 | 75 |
| LNI | 13 | 0 |
| Adjuvant Therapies (%) | ||
| Hormone Therapy | 34 | 9 |
| Radiation Therapy | 39 | 36 |
| Salvage Therapies (%) | ||
| Hormone Therapy | 39 | 29 |
| Radiation Therapy | 31 | 64 |
| 5 year Overall Cohort Metastatic Risk | 0.076 | 0.071 |
| Range of Risks for Cohort | (0.0095, 0.48) | (0.0097, 0.32) |
| Proportion Classified as High Risk According to GC | 41.46% | 45.32% |
SD = standard deviation; ECE = extracapsular extension; SVI = seminal vesicle invasion; PSM = positive surgical margin; LNI = lymph node involvement; GC = genomic classifier; TJU = Thomas Jefferson University; Ref. = reference
*Note, three patients were excluded from this original cohort due to unknown ECE status; Overall cohort metastatic risk, range of risks for cohort, and proportion classified as high risk according to GC was based on the reweighted cohort of 808 patients from the original cohort of 216 patients.